A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy
- PMID: 22366800
- DOI: 10.1093/brain/awr336
A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy
Abstract
Multiple sclerosis may have a non-progressive symptomatology for decades; however, it is not clear whether the disease activity may abate completely. We identified a cohort of patients, resident in Gothenburg at the time of disease onset, between the years 1950-64 (n = 307). These geographical and temporal restrictions, along with favourable conditions for a 'spider' epidemiological study, were optimal for an unbiased selection; this 15-year incidence cohort was essentially followed prospectively for 37-59 years after onset. The shortest follow-up time for patients without primary or secondary progression was 45 years. For patients with an initial relapsing-remitting course and multiple sclerosis diagnosis according to the Poser criteria (n = 202), the probability of non-progressive disease after 40 years was 22% (standard error 3.0%), and after 50 years it was 14% (standard error 3.2%). For attack onset including patients with possible multiple sclerosis, the corresponding probabilities after 40 and 50 years were 35% (standard error 3.3%) and 28% (standard error 3.5%), respectively. At the last follow-up in 2009-10, when patients reached the average age of the Swedish population life expectancy, only 13 patients from the multiple sclerosis diagnosis cohort, according to the Poser criteria, remained alive and non-progressive. Their annualized attack frequency diminished with time from 0.29 to 0.015. These patients had been functioning well socially. Nine patients had an Expanded Disability Status Scale score of 0-2.5, and four patients had a score of 3 or 3.5, with deficits dating back to attacks decades ago. Eight patients participated in a complete neuropsychological examination, which showed a slight difference (P < 0.01) concerning verbal memory and executive function compared to an age and socially matched reference group, whereas results for five other cognitive domains were within the normal range. Magnetic resonance images fulfilled the Barkhof-Tintoré criteria for multiple sclerosis in 10 of 11 patients, with conspicuously few subcortical lesions relative to extensive periventricular lesions and lesions extending from the inferior midline aspect of the corpus callosum. Prediction of the non-progressive stage was possible with moderate hazard ratios and low sensitivity. Early features that predicted a non-progressive course were complete remission of the onset attack, low or moderate initial relapse frequency and-when the patients with possible multiple sclerosis were included-dominating afferent symptoms. The clinical disease activity had abated in these 13 patients, with the caveat that transition to secondary progression continued to occur after four decades, albeit with decreasing risk.
Similar articles
-
Natural history of multiple sclerosis: a unifying concept.Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16. Brain. 2006. PMID: 16415308
-
Relapses and progression of disability in multiple sclerosis.N Engl J Med. 2000 Nov 16;343(20):1430-8. doi: 10.1056/NEJM200011163432001. N Engl J Med. 2000. PMID: 11078767
-
The natural history of primary progressive multiple sclerosis.Neurology. 2009 Dec 8;73(23):1996-2002. doi: 10.1212/WNL.0b013e3181c5b47f. Neurology. 2009. PMID: 19996074
-
Natural history of multiple sclerosis: risk factors and prognostic indicators.Curr Opin Neurol. 2007 Jun;20(3):269-74. doi: 10.1097/WCO.0b013e32812583ad. Curr Opin Neurol. 2007. PMID: 17495619 Review.
-
Pediatric multiple sclerosis.J Child Neurol. 2012 Nov;27(11):1378-83. doi: 10.1177/0883073812452784. Epub 2012 Aug 21. J Child Neurol. 2012. PMID: 22914372 Review.
Cited by
-
Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.Front Neurol. 2019 Feb 22;10:132. doi: 10.3389/fneur.2019.00132. eCollection 2019. Front Neurol. 2019. PMID: 30853935 Free PMC article.
-
Disability in multiple sclerosis: a reference for patients and clinicians.Neurology. 2013 Mar 12;80(11):1018-24. doi: 10.1212/WNL.0b013e3182872855. Epub 2013 Feb 20. Neurology. 2013. PMID: 23427319 Free PMC article.
-
Multiple sclerosis: time for early treatment with high-efficacy drugs.J Neurol. 2024 Jan;271(1):105-115. doi: 10.1007/s00415-023-11969-8. Epub 2023 Oct 18. J Neurol. 2024. PMID: 37851189 Free PMC article. Review.
-
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.J Neurol. 2015 May;262(5):1148-63. doi: 10.1007/s00415-015-7674-y. Epub 2015 Feb 26. J Neurol. 2015. PMID: 25712541
-
Intrathecal Baclofen Dosage for Long-Term Treatment of Patients With Spasticity Due to Traumatic Spinal Cord Injuries or Multiple Sclerosis.Ann Rehabil Med. 2019 Oct;43(5):555-561. doi: 10.5535/arm.2019.43.5.555. Epub 2019 Oct 31. Ann Rehabil Med. 2019. PMID: 31693845 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical